Cicatricial contraction of preretinal fibrous membrane is a cause of severe vision loss in proliferative vitreoretinal diseases such as proliferative diabetic retinopathy (PDR) and proliferative vitreoretinopathy (PVR). TGF-␤ is overexpressed in the vitreous of patients with proliferative vitreoretinal diseases and is also detectable in the contractile membranes. Therefore, TGF-␤ is presumed to contribute to the cicatricial contraction of the membranes, however, the underlying mechanisms and TGF-␤'s importance among various other factors remain to be elucidated. Vitreous samples from PDR or PVR patients caused significantly larger contraction of hyalocyte-containing collagen gels, compared with nonproliferative controls. The contractile effect was strongly correlated with the vitreal concentration of activated TGF-␤2 (r ‫؍‬ 0.82, P < 0.0001). proliferative diabetic retinopathy ͉ proliferative vitreoretinopathy ͉ fibrosis ͉ wound healing
P
roliferative vitreoretinal diseases, such as proliferative diabetic retinopathy (PDR) and proliferative vitreoretinopathy (PVR), remain common causes of severe vision loss despite recent advancements in vitreoretinal surgery (1, 2) . A better understanding of the pathogenesis of these diseases is critical for the development of urgently needed new pharmacologic treatments.
Excessive wound healing in proliferative vitreoretinal diseases leads to formation of cicatricial preretinal fibrous membranes. This process is characterized by the migration and proliferation of various cell types, including hyalocytes, retinal pigment epithelial cells (RPE), glial cells, and myofibroblast-like cells of unknown origin. These cells organize into the proliferative membrane (3, 4) . Hyalocytes are found in the cortical vitreous in the vicinity of the inner retinal surface (5) . Morphological studies suggest that hyalocytes may belong to the monocyte/ macrophage lineage (6, 7) . Hyalocytes are thought to originate from the bone marrow and differentiate in the vitreous (8) . Under physiologic conditions, hyalocytes contribute to the transparency of the vitreous (9) , however, they may also be involved in diseases of the vitreoretinal interface (3, 10) . Specifically, in diabetic eyes, hyalocytes are found in higher numbers and their morphology is distinct from that in normal eyes (11) .
Contraction of the proliferative membranes causes retinal detachment, which leads to photoreceptor apoptosis and ultimately to vision loss. Growth factors, such as TGF-␤, PDGF (12, 13) , insulin-like growth factor-1 (IGF-1) (13) , and endothelins (14) regulate the cicatricial contraction of the preretinal membranes.
TGF-␤ is a multifunctional cytokine, regulating pivotal biological responses, such as differentiation, apoptosis, migration, immune cell function, and ECM synthesis (15) . TGF-␤ has three isoforms (TGF-␤1, -␤2, and -␤3) and is secreted as a biologically inactive latent complex. Latent TGF-␤ is activated by various chemical or enzymatic treatments (16) (17) (18) .
TGF-␤ has been implicated in tissue contraction in fibrous diseases, such as liver cirrhosis, pulmonary fibrosis, and systemic sclerosis (19) . In the eye, TGF-␤ is overexpressed in the vitreous of patients with PDR and PVR (20, 21) and is also identified in proliferative membranes in these diseases (22) . Specifically, the concentration of TGF-␤2, the predominant TGF-␤ isoform in the posterior segment of the eye (23) , significantly correlates with the severity of PVR (20) . In addition, we previously showed that TGF-␤2 contributes to transdifferentiation of hyalocytes into ␣-smooth muscle actin (␣-SMA) positive myofibroblast-like cells that cause collagen gel contraction (12) . Taken together, TGF-␤ is presumed to contribute to the contraction of the cicatricial membranes in PDR and PVR. However, the direct evidence of the effect and the importance of TGF-␤ among various factors in the vitreous remain to be elucidated.
Phosphorylation of myosin light chain (MLC) is associated with actin-myosin interaction to form stress fibers and contractile rings, facilitating cell contraction and motility (24, 25) . Rho-kinase (ROCK), a target protein of Rho, is implicated in cell adhesion, migration, proliferation, and apoptosis. ROCK regulates MLC phosphorylation both directly and via inactivation of the MLC phosphatase (25, 26) . Previously we showed that TGF-␤2 activates Rho, leading to MLC phosphorylation in hyalocytes (12, 21) . A potent and selective ROCK inhibitor, fasudil, suppresses TGF-␤2-induced MLC phosphorylation and collagen gel contraction by hyalocytes (12) .
In the present study, we investigate the role of TGF-␤ in mediating cicatricial contraction in proliferative vitreoretinal diseases using vitreous samples. Furthermore, we demonstrate the underlying molecular mechanisms and the central role of ROCK in the cicatrical contraction, downstream of TGF-␤ and other growth factors.
Results

TGF-␤1
and -␤2 Concentration in the Vitreous. We quantified the concentration of total (activated and latent) TGF-␤1 and -␤2 protein in vitreous from PDR or PVR patients and nonproliferative controls [macular hole (MH) or rhegmatogenous retinal detachment (RRD)]. Total TGF-␤1 was not detectable in MH or RRD samples. In contrast, total TGF-␤1 was found in some of PDR and PVR samples (PDR, 115.4 Ϯ 44.6 pg/ml; PVR, 12.7 Ϯ 8.5 pg/ml) (Fig. 1A) . Activated TGF-␤1 was not detectable in any of the groups (data not shown). Vitreal concentrations of total TGF-␤2 in patients with PDR (5563 Ϯ 765 pg/ml) and PVR (4283 Ϯ 455 pg/ml) were significantly higher than those from MH (2213 Ϯ 34.3 pg/ml) and RRD (2643 Ϯ 403 pg/ml) (Fig. 1B) . Analogously, the vitreal concentrations of activated TGF-␤2 in patients with PDR (180.3 Ϯ 20.4 pg/ml) and PVR (211.9 Ϯ 21.5 pg/ml) were significantly higher than those from MH (86.8 Ϯ 9.1 pg/ml) and RRD (105.2 Ϯ 7.4 pg/ml) (Fig. 1C) . In addition, there was a significant correlation between the concentrations of total and activated TGF-␤2 protein in the vitreous (r ϭ 0.37, P ϭ 0.026) (Fig. 1D) . The average percent ratio of activated TGF-␤2 to total TGF-␤2 of all vitreal samples was 4.5 Ϯ 0.3%.
Role of TGF-␤ in Vitreous-Induced Collagen Gel Contraction. Recombinant TGF-␤2 caused significant contraction of hyalocytecontaining collagen gels (58.7 Ϯ 0.4% compared to the diameter of the control gels, n ϭ 24, P Ͻ 0.0001; paired t-test), which was effectively blocked (99.8 Ϯ 0.3%, P Ͻ 0.0001 vs. TGF-␤2) with an anti-TGF-␤ (-␤1, -␤2, and -␤3) mAb, while a mouse control IgG did not affect the TGF-␤2-induced contraction ( Fig. 2A) .
Vitreous samples with proliferative (PDR, 64.6 Ϯ 2.1% and PVR, 61.8 Ϯ 2.1%) and nonproliferative (MH, 74.1 Ϯ 1.7% and RRD, 73.9 Ϯ 1.5%) vitreoretinal diseases significantly decreased the diameter of hyalocyte-containing collagen gels, compared with DMEM-treated control (n ϭ 6, P Ͻ 0.0001 in each group; Mann-Whitney U-test). Furthermore, PDR or PVR vitreous caused hypercontraction of hyalocyte-containing collagen gels as compared with vitreous with MH (PDR, P ϭ 0.01 and PVR, P ϭ 0.007; Mann-Whitney U-test) or RRD (PDR, P ϭ 0.007 and PVR, P ϭ 0.004). The vitreous-induced collagen gel contraction was significantly suppressed with an anti-TGF-␤ mAb (MH, 99.1 Ϯ 0.3%; RRD, 94.2 Ϯ 1.6%; PDR, 86.2 Ϯ 3.4% and PVR, 86.6 Ϯ 1.5%, P Ͻ 0.0001 in each; paired t-test) ( Fig. 2 A and B) , but was not affected by a mouse control IgG [supporting information (SI) Fig. S1 ]. The concentration of activated TGF-␤2 in the vitreal samples showed a strong correlation with the reduction in diameter of the gels (r ϭ 0.82, P Ͻ 0.0001). However, there was no significant correlation between the concentration of total TGF-␤2 and the gel diameter (r ϭ 0.39, P ϭ 0.06) (Fig. 2 C and D) .
Impact of ROCK Inhibition on PDR/PVR-Induced Collagen Gel Contrac-
tion. Both TGF-␤ inhibition with a mAb and ROCK inhibition with fasudil almost completely suppressed the TGF-␤2-induced collagen gel contraction (average diameter of the gels compared with the medium-treated controls: TGF-␤2, 63.4 Ϯ 4.1%; TGF-␤2/anti-TGF-␤, 99.3 Ϯ 0.4%; TGF-␤2/fasudil, 98.9 Ϯ 0.7%) (Fig.  3A) . However, TGF-␤ blockade significantly but incompletely inhibited the collagen gel contraction, induced by PDR/PVR vitreal samples (PDR, 64.4 Ϯ 2.3%; PDR/anti-TGF-␤, 89.5 Ϯ 1.1%; PVR, 64.6 Ϯ 0.3%; and PVR/anti-TGF-␤, 88.2 Ϯ 2.8%). In comparison, fasudil almost completely suppressed the contraction of collagen gels treated with PDR (99.3 Ϯ 0.5%) and PVR (95.9 Ϯ 1.5%) samples. The impact of fasudil on PDR/ PVR-induced collagen gel contraction was significantly higher than that of TGF-␤ blockade ( Fig. 3 B and C) .
Role of TGF-␤ in the PDR/PVR-Induced ␣-SMA Expression. Recombinant TGF-␤2 enhanced the expression of ␣-SMA protein, an indicator of myofibroblastic transdifferentiation (2.5 Ϯ 0.2 folds compared to medium-treated control), which was significantly reduced by anti-TGF-␤ mAb treatment (1.1 Ϯ 0.04 folds). However, fasudil did not reduce TGF-␤2-induced ␣-SMA upregulation (2.6 Ϯ 0.3 folds) (Fig. 4A) . The PDR and PVR vitreal samples caused a significant 1.9 Ϯ 0.1 and 1.8 Ϯ 0.1 fold increase in ␣-SMA expression compared with the medium-treated controls. These increases in ␣-SMA expression were significantly suppressed by TGF-␤ inhibition (PDR/anti-TGF-␤, 1.1 Ϯ 0.1 folds and PVR/anti-TGF-␤, 1.1 Ϯ 0.1 folds). However, fasudil did not significantly reduce the increase in ␣-SMA expression, caused by PDR (1.95 Ϯ 0.1 folds) or PVR (1.9 Ϯ 0.1 folds) vitreous (Fig. 4 B and C) . Immunohistochemical analysis of the hyalocyte-containing collagen gels showed increased ␣-SMA expression with TGF-␤2 and PDR vitreous treatment (Fig. S2 A,  B, and D) . Fasudil disrupted ␣-SMA organization without affecting its expression (Fig. S2 C and E) . Impact of ROCK Inhibition on In Vivo Experimental PVR. In the vehicle-treated controls, PVR progressed with time up to 14 days after induction (Fig. 6A ). Fasudil at a final intravitreal concentration of 10 M inhibited only the early progression of PVR up Fig. 3 . Suppressive effect of fasudil on PDR/PVR-induced collagen gel contraction. Hyalocyte-containing collagen gels were stimulated with recombinant TGF-␤2 (A), PDR vitreous (B), or PVR vitreous (C) (n ϭ 3, each group) with or without anti-TGF-␤ mAb or fasudil (20 M) for 3 days. Thereafter, the gels were photographed and the diameter of the gels was measured and statistically analyzed. Representative results are shown. * , P Ͻ 0.05; ** , P Ͻ 0.01; NS, not significant (paired t test). The gels from Fig. 3 were dissolved and the cells were isolated and lysed. ␣-SMA expressions were examined by Western blot analysis. Loaded cell lysates in A, B, and C were from the gels in Fig. 3 A, B , and C, respectively. Representative blots are shown. Signal intensities were quantified and expressed as percentages of the ␣-SMA/GAPDH ratio compared with control (treated with DMEM). * , P Ͻ 0.05; ** , P Ͻ 0.01; NS, not significant (paired t test). to the third day after disease induction. In contrast, fasudil at a concentration of 30 M effectively suppressed the progression of the PVR from day 3 up to day 14. In addition, treatment of stage-2 PVR with fasudil, from the third or fifth day after induction, when proliferative membranes have already formed and adhered to retinal tissue, effectively blocked PVR progression. The concentrations of both total TGF-␤1 and -␤2 and activated TGF-␤2 were significantly elevated in the vitreous with stage-5 PVR compared with control vitreous collected before disease induction (Fig. S3 A-C) . Activated TGF-␤1 was not detectable in any sample (data not shown). In the vehicle-treated eyes, contractile proliferative membranes formed (stage-5 PVR), causing total retinal detachment (Fig. 6B) . In contrast, in the eyes treated with 30 M fasudil from stage-2 PVR, stereomicroscopy revealed noncontractile membranes that were adherent to the retinal surface (Fig. 6C) . Immunohistochemistry revealed expression and organization of ␣-SMA in the contractile preretinal proliferative membranes in the vehicle-treated eyes (Fig. 6 D and F) . In fasudil-treated eyes, ␣-SMA was similarly expressed, however, its organization was disrupted and the membranes were noncontractile (Fig. 6 E and G) . (Fig. S4A) . The morphological examination of the eyes that were injected with 30 M fasudil did not show signs of retinal damage or inflammatory cell infiltration in light microscopy or transmission EM (Fig. S4 B-E) . Furthermore, TUNEL positive cells were found in the outer and inner nuclear layers of detached retinas from eyes with PVR, while no TUNEL positivity was found in 30 M fasudil-treated eyes (Fig. S4 F and G) . Unlike in humans and rodents, in rabbits blood vessels are limited to the medullary ray. Therefore, electroretinographic and histological analysis were also performed in fasudil-treated rats. Intravitreal fasudil did not show any obvious toxicity up to 100 M concentration (Fig. S5) . Furthermore, while 30 M fasudil slightly but significantly reduced serum-induced proliferation of cultured rabbit conjunctival fibroblasts, the same concentration of fasudil did not affect the number of cells with serum-free DMEM or control vitreous (Fig. S6) .
Discussion
This study elucidates the contractile property of human vitreous and provides direct evidence for the critical role of TGF-␤ in the pathogenesis of proliferative vitreoretinal diseases such as PDR and PVR. Furthermore, we demonstrate the therapeutic potential of fasudil, a potent and selective ROCK inhibitor, in the management of these diseases.
Vitreous from patients with PDR/PVR significantly enhanced contraction of hyalocyte-containing collagen gels, compared with vitreous from patients with nonproliferative diseases. This suggested the existence of vitreal factors that initiate a cascade of events leading to cicatricial contraction of the proliferative membranes in PDR/PVR patients. This insight is of clinical relevance, as it indicates that removal of the vitreous, i.e., through vitrectomy, would diminish the pathogenic factors and might be an effective treatment in a subset of patients with these diseases.
PDR/PVR-induced collagen gel contraction was dramatically suppressed by TGF-␤ blockade, emphasizing the central role of this cytokine in the events that lead to cicatricial contraction of the proliferative membranes. Our results further indicate that TGF-␤2 is the predominantly responsible isoform in the pathogenesis. This may be because of the fact that the concentrations of total and activated TGF-␤1 were negligibly low, compared with those of TGF-␤2, in line with previous reports (20, 23) . Furthermore, there was a strong correlation between the concentrations of activated TGF-␤2 and the contractile effects, emphasizing the important role of this isoform in the pathology of PDR or PVR.
Vitreous from patients with nonproliferative diseases such as MH and RRD also caused significant collagen gel contraction, albeit substantially less than vitreous from PDR or PVR patients, which was effectively suppressed by TGF-␤ blockade. TGF-␤ is constitutively expressed in the vitreous at much lower concentrations than found in PDR/PVR patients. TGF-␤ contributes to the ocular immune privilege (27) , and its expression under normal conditions suggests that normal vitreous might also have contractile properties. However, even though normal vitreous and vitreous in nonproliferative diseases have contractile potential, without proliferative membranes, retinal traction may not occur in vivo. This suggests that the formation of proliferative membranes, which is regulated by cytokines other than TGF-␤, including PDGF (6), hepatocyte growth factor (HGF) (28) , and monocyte chemotactic protein-1 (MCP-1) (29) , is also critical in the pathogenesis of proliferative vitreoretinal diseases.
Collagen gel contraction strongly correlated with the concentration of activated TGF-␤2 in the vitreous, but not with that of total (activated ϩ latent) TGF-␤2. Our results suggest that only activated TGF-␤2 in the vitreous causes collagen gel contraction, while latent TGF-␤2 may serve as a precursor pool for the generation of activated TGF-␤2. In addition, there was a mild but significant correlation between activated and total TGF-␤2. Therefore, the significantly elevated concentration of total TGF-␤2 in the vitreous in proliferative vitreoretinal diseases may also be clinically relevant.
Our results provide novel molecular insight into the mechanism of contraction in PDR/PVR. PDR/PVR vitreous enhanced ␣-SMA expression and MLC phosphorylation, both of which were dramatically suppressed by TGF-␤ blockade. This suggests that PDR/PVR vitreous may exert their procontractile property by furthering myofibroblastic transdifferentiation or MLC phosphorylation in targeted cells, such as hyalocytes. Furthermore, our results single out TGF-␤ as one of the main factors responsible for the procontractile property of PDR/PVR vitreous. However, other factors may also significantly contribute to the cicatricial contraction, as TGF-␤ blockade does not abolish the procontractile property of PDR/PVR vitreous. PDGF, IGF-1, and endothelins are also thought to be involved in the cicatricial contraction of the proliferative membrane (12) (13) (14) , albeit to a lesser extent than TGF-␤, as suggested in the present study.
Fasudil abolished the PDR/PVR-induced collagen gel contraction. While PDR/PVR-induced ␣-SMA expression was unaffected by fasudil, ␣-SMA organization was effectively disrupted. This suggests that fasudil might diminish the contractile property of proliferative membranes by affecting ␣-SMA organization, in line with previous findings (30) . In addition, fasudil almost completely suppressed MLC phosphorylation, a contraction-associated molecule and a mediator of TGF-␤ signaling. Previously we showed that PDGF causes transient MLC phosphorylation in hyalocytes and that fasudil completely blocks it (12) . Furthermore, IGF-1 and endothelin-1-induced contraction are in part dependent on MLC phosphorylation through the activation of the Rho/ROCK pathway and are effectively suppressed by ROCK inhibitors (31) (32) (33) . Furthermore, ROCK inhibitors reduce cell adhesion, migration, and proliferation, and ECM production, which contribute to the formation of proliferative membranes (21, 25, 26) . Our results indicate that ROCK inhibition by fasudil suppresses PVR progression even after the proliferative membranes are formed and have adhered to the retina.
Because ROCK is the common downstream mediator of various growth factors, including TGF-␤, which lead to cicatrical contraction, and ROCK inhibition with fasudil reduces PDR/ PVR-induced contraction more strongly than TGF-␤ inhibition, ROCK might be a more attractive therapeutic target than TGF-␤ in the treatment of cicatricial contraction of preretinal membranes. Furthermore, because TGF-␤ is a multifunctional cytokine, its inhibition may cause considerable side effects (34) . In contrast, fasudil has already proven to be relatively safe and effective in the treatment of cardiovascular diseases, including cerebral and coronary vasospasm, angina, hypertension, pulmonary hypertension, and heart failure (35) .
In summary, this work demonstrates the therapeutic potential of fasudil in halting the progression of experimental PVR, without morphological or functional indication of retinal toxicity. Our results suggest that ROCK inhibition might become a therapeutic strategy in the management of proliferative vitreoretinal diseases such as PDR and PVR.
